Cannabis Law Report

JUNE 7, 2021

IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.

Clinical Trials 105

Clinical Trials Patients THC Safety 105

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers. For more information, visit www.inmedpharma.com.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

MMJ Recs

NOVEMBER 20, 2023

This article delves into the science behind medical marijuana, focusing on cannabinoids, the active compounds found in the cannabis plant, and their remarkable therapeutic effects. We’ll explore the diverse range of cannabinoids and their health benefits, providing insights into how these compounds are revolutionizing healthcare.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Cannabis Law Report

DECEMBER 14, 2021

IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The trial was conducted as a multiple ascending dose (MAD) study.

Clinical Trials 52

Clinical Trials Safety Data Patients 52

Cannabis Law Report

JULY 28, 2021

On 1 June 2021, the Group announced an agreement with Voisin Consulting SARL (“VC”), a life sciences consultancy comprising over 200 professionals in the UK, US and India, with expertise in medical devices, cannabinoids, neurological disorders and addictions.

Cannabinoids 105

Cannabinoids Clinical Trials Safety Medicine 105

Kind Meds (Cannabis Education Blog)

NOVEMBER 16, 2022

CBN is a popular cannabinoid, but what should we know about CBN and sleep? This minor cannabinoid has always existed in the cannabis plant in small quantities, but it is gaining in popularity for its potential healing properties. CBN is found in the cannabis sativa plant, though it can be produced semi-synthetically.

Sleep 94

Sleep Cannabinoids THC CBD 94

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 52

Clinical Trials Data Patients THC 52

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. Annabelle Manalo-Morgan, Director and Lead Scientific Advisor of Flora Growth.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Leafly

OCTOBER 4, 2022

A drug that blocks the brain's cannabinoid receptors is now in clinical trials and showing promising results. The post Are you too high? A promising new ‘comedown drug’ may be on the way appeared first on Leafly.

Clinical Trials 104

Clinical Trials Cannabinoids Medicine THC 104

Cannabis Law Report

JULY 23, 2021

The Denver cannabis company MedPharm can now ramp up its research into the effects marijuana has on Alzheimer’s disease. When you’re talking about wanting to do an actual clinical trial, you need a diversity of people that participate and one state just does not have the diversity of people that are required,” Towle said.

DEA 105

DEA Clinical Trials Cannabinoids Extraction 105

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers. For more information, visit www.inmedpharma.com.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

The Joint Blog

NOVEMBER 8, 2020

The study states: “[T]he impact of the intervention on quality of life in the cannabis group participants was evident, resulting in reports of well-being and more energy for activities of daily living. Pain attacks were also reduced.”. mg/mL of THC and 0.51 Results: There were no significant differences on baseline FIQ score between groups.

Clinical Trials 49

Clinical Trials Oil Therapy Marijuana 49

NORML

APRIL 30, 2020

.” The CDC’s interest in alternative methods of chronic pain management may be of particular significance to many medical cannabis patients. According to state-registry records, “Chronic pain is currently and historically the most common qualifying condition reported by medical cannabis patients (67.5

Chronic Pain 341

Chronic Pain Clinical Trials Data Patients 341

Cannabis Law Report

AUGUST 28, 2022

Cannabinoids are a class of chemical compounds found in the cannabis plant. There are over 100 cannabinoids, and they are responsible for the plant’s therapeutic effects. Cannabinoids interact with our body’s endocannabinoid system, which regulates many important functions, including mood, appetite, and pain.

Cannabinoids 52

Cannabinoids Trichome Treatment Clinical Trials 52

Cannabis Law Report

JANUARY 10, 2022

Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. minor cannabinoids market size is expected to reach USD 26.2

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

NORML

MARCH 30, 2020

There is an absence of clinical data supporting the efficacy of CBD as an antiviral agent, according to a systematic literature review published in the journal Cannabis and Cannabinoid Research. However, this data was based solely on preclinical findings. ” — appears online here.

CBD 295

CBD Clinical Trials Data Treatment 295

Cannabis Law Report

SEPTEMBER 2, 2021

The use of cannabinoids in the treatment of medical conditions offers major opportunities and challenges to anyone operating in the space. In Europe, there is a clear trend towards the use of more precise formulations of unapproved cannabis products as well as pharmaceutical products.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Cannabinoids 105

Cannabis Law Report

MARCH 7, 2023

Incannex Healthcare Limited, a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, announced that it has engaged Catalent (Catalent) to develop and manufacture a cGMP-grade psilocybin drug product for: (1) use in Incannex’s proprietary psilocybin-assisted psychotherapy (..)

Clinical Trials 52

Clinical Trials Therapy Pharmaceutical Medicine 52

The Cannigma

OCTOBER 11, 2021

The majority of people who use the cannabinoid cannabigerol (CBG) for medical reasons find it to be helpful or very helpful in treating a variety of health conditions, according to the findings of a recent survey. No clinical trial was used in the compilation of the study. Why is CBG ‘the mother of all cannabinoids?’.

Conditions 132

Conditions Clinical Trials Chronic Pain Cannabinoids 132

Cannabis Law Report

AUGUST 19, 2021

Legal cannabis consumption and it isn’t even legal yet. If and when cannabis is actually properly regulated we’re sure the UK can be a world beater!! Cannabidiol or CBD, which is most commonly sold as oil at high street retailers, is one of the active ingredients of non-psychoactive cannabis.

Cannabinoids 105

Cannabinoids Seed-To-Sale Clinical Trials CBD 105

Canna Care Docs

OCTOBER 3, 2023

Natural plant therapy , and cannabis specifically, has been studied for its effectiveness in alleviating and treating many of these physiological and emotional symptoms that come into play with a terminal illness. However, many of these pharmaceutical medications can just induce more unpleasant, debilitating effects on those who are ill.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

NORML

JANUARY 31, 2019

Seventy-five percent of military veterans say that they would consider using either “cannabis or cannabinoid products as a treatment option,” according to member survey data compiled by the group Iraq and Afghanistan Veterans of America (IAVA). The organization represents over 400,000 veterans nationwide.

Clinical Trials 193

Clinical Trials Chronic Pain Data Treatment 193

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

AUGUST 23, 2021

Oxford Cannabinoid Technologies Holdings plc. At the end of the programme, Evotec will provide the Company with a submission-ready regulatory document which will be used for submissions to regulatory agencies, as well as drug-batch approved and ready for First Time in Human clinical trials. & Notice of 2021 Final Results.

Cannabinoids 98

Cannabinoids Research and Development Clinical Trials Packaging 98

Cannabis Law Report

FEBRUARY 2, 2022

– Flora’s research division, Flora Pharma, files USPTO provisional patent application on a cannabinoid-based formula. – Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under an EUA from INVIMA (Colombian FDA).

Cannabinoids 52

Cannabinoids Clinical Trials Events Cultivation 52

Cannabis Law Report

SEPTEMBER 2, 2022

LOBEF signed a deal with Cantheon Capital, a development of cannabinoids and psychedelic drugs supporter, for aggregate proceeds to the company of up to $1.5 Funding for psychedelics research and clinical trials is certainly here to stay. Psychedelics biopharma company Lobe Sciences Ltd. Read more.

Clinical Trials 52

Clinical Trials Research and Development Cannabinoids Medicine 52

United Patients Group

JANUARY 8, 2023

Cannabis and the Immune System. Cannabis and the Immune System. In fact, cannabis has been used for thousands of years as a medicine. Cannabis has also been used for centuries to treat gastrointestinal disorders, epilepsy, rheumatism and malaria. Cannabis has Antiviral, Antibacterial and Fungal Properties.

Blood Pressure 105

Blood Pressure Sleep Cannabinoids Clinical Trials 105

The Cannigma

JUNE 14, 2021

For more than 50 years, if you wanted to do cannabis research in the United States, federal law said you had to get the cannabis from the University of Mississippi. The BRC is among the dozens of organizations that have received preliminary approval from the DEA to cultivate cannabis.

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

PrestoDoctor

SEPTEMBER 15, 2023

However, recent research suggests that cannabis may be a promising option for those seeking relief from OCD symptoms. We’ll explore the ways in which cannabis can help ease OCD symptoms and compulsions and how to use it effectively. We’ll also examine the potential benefits and drawbacks of using cannabis to manage OCD.

Research and Development 105

Research and Development Therapy Treatment Strains 105

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

The Cannigma

MARCH 7, 2022

So much attention is placed upon THC and CBD that sometimes the less abundant cannabinoids are forgotten about or not appreciated fully. Yet cannabinol (CBN), the first cannabinoid ever discovered by modern scientists, is slowly making a comeback in the cannabis industry. . The best online schools for medical cannabis training.

THC 140

THC Sleep Clinical Trials Cannabinoids 140

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

MARCH 16, 2022

A key subcommittee tasked with exploring medical cannabis reform and regulations finally met in Spain, which will hopefully help yield future movement. of the authorized clinical trials with cannabinoids and about the doubts that currently exist.

Clinical Trials 52

Clinical Trials Chronic Pain Medicine Cannabinoids 52

Medicinal Marijuana Association

FEBRUARY 11, 2024

You may have heard whispers of cannabis being used to address a specific eye condition, but what does the research truly reveal about its effectiveness? The potential link between cannabis and glaucoma treatment is a topic of ongoing investigation, stirring both curiosity and caution within the medical community.

Treatment 52

Treatment Blood Pressure Conditions Clinical Trials 52

Cannabis Law Report

AUGUST 10, 2022

MediPharm to design, manufacture and supply a liquid oral cannabis study drug for the Phase 2 Life’s end Benefits of cannabidiol and tetrahydrocannabinol (LiBBY) study, to be conducted in the U.S., ” Study Details – provided by Alzheimer’s Clinical Trial Consortium. across 20 sites. BARRIE, ON , Aug.

Clinical Trials 52

Clinical Trials Medicine Pharmaceutical THC 52

Cannabis Law Report

JULY 4, 2019

The manuscript is part of EMMAC’s collaboration with Imperial College London, forged to deliver a long-term comprehensive research programme designed to inform and shape the future of the medical cannabis therapeutic industry. About EMMAC.

Cannabinoids 40

Cannabinoids Clinical Trials Chronic Pain Medicine 40